Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options is a research paper published in Pharmacology & Therapeutics (2022). On theSindex it has a DataRank of 0. It has been cited 253 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Intramural NIH HHS
Grant: Z99 CA999999
Government of South Australia
National Cancer Institute
MeSH Terms
Keywords
Additional file 1 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis
Additional file 1 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis
Additional file 2 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis
Additional file 2 of Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis
Additional file 3 of Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses
Additional file 3 of Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses
Additional file 1 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 1 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 2 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 2 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 3 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 3 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 7 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 7 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 2 of Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses
Additional file 4 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 5 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 6 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 5 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells
Additional file 4 of Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells